Three-year EFS according to characteristics of the 56 HR patients
| . | n (%) . | 3-y EFS (SE), % . | P . |
|---|---|---|---|
| Sex | |||
| Male | 24 (42.9) | 67.5 (10.2) | .255 |
| Female | 32 (57.1) | 50.0 (8.8) | |
| Age at diagnosis, d | |||
| 0-89 | 21 (37.5) | 62.0 (11.4) | .719 |
| 90-179 | 35 (62.5) | 54.1 (8.5) | |
| WBCs at diagnosis, ×109/L | |||
| <100 | 20 (35.7) | 73.7 (10.1) | .170 |
| 100 to <300 | 14 (25.0) | 54.2 (13.8) | |
| ≥300 | 22 (39.3) | 43.1 (10.8) | |
| CNS status at diagnosis* | |||
| CNS-1 | 29 (51.8) | 58.6 (9.2) | .815 |
| CNS-2 | 16 (28.6) | 46.9 (12.9) | |
| CNS-3 | 10 (17.9) | 63.5 (16.9) | |
| Unknown | 1 (1.8) | — | |
| KMT2A fusion | |||
| t(4;11)/KMT2A-AFF1 | 28 (50.0) | 53.6 (9.4) | .595 |
| t(9;11)/KMT2A-MLLT3 | 3 (5.4) | 100 | |
| t(11;19)/KMT2A-MLLT1 | 14 (25.0) | 57.1 (13.2) | |
| Other KMT2A-r | 11 (19.6) | 50.0 (17.7) | |
| Interfant-06 risk group† | |||
| Interfant-MR | 23 (41.1) | 72.9 (9.5) | .051 |
| Interfant-HR | 33 (58.9) | 45.4 (9.0) | |
| Day 8 prednisolone response | |||
| PGR | 31 (55.4) | 60.1 (8.9) | .615 |
| PPR | 25 (44.6) | 52.5 (10.4) | |
| BM status at TP2‡ | |||
| M1 | 47 (90.4) | 59.5 (7.2) | .205 |
| M2 | 4 (7.7) | 25.0 (21.7) | |
| M3 | 0 (0.0) | — | |
| Not evaluated | 1 (1.9) | — | |
| FCM-MRD at TP2‡ | |||
| <0.01% | 29 (56.9) | 65.5 (8.8) | .036 |
| ≥0.01% | 19 (37.3) | 36.8 (11.1) | |
| Not evaluated | 3 (5.9) | — | |
| FCM-MRD at TP3‡ | |||
| <0.01% | 33 (64.7) | 69.6 (8.0) | <.001 |
| ≥0.01% | 8 (15.9) | 0 | |
| Not evaluated | 10 (19.6) | — |
| . | n (%) . | 3-y EFS (SE), % . | P . |
|---|---|---|---|
| Sex | |||
| Male | 24 (42.9) | 67.5 (10.2) | .255 |
| Female | 32 (57.1) | 50.0 (8.8) | |
| Age at diagnosis, d | |||
| 0-89 | 21 (37.5) | 62.0 (11.4) | .719 |
| 90-179 | 35 (62.5) | 54.1 (8.5) | |
| WBCs at diagnosis, ×109/L | |||
| <100 | 20 (35.7) | 73.7 (10.1) | .170 |
| 100 to <300 | 14 (25.0) | 54.2 (13.8) | |
| ≥300 | 22 (39.3) | 43.1 (10.8) | |
| CNS status at diagnosis* | |||
| CNS-1 | 29 (51.8) | 58.6 (9.2) | .815 |
| CNS-2 | 16 (28.6) | 46.9 (12.9) | |
| CNS-3 | 10 (17.9) | 63.5 (16.9) | |
| Unknown | 1 (1.8) | — | |
| KMT2A fusion | |||
| t(4;11)/KMT2A-AFF1 | 28 (50.0) | 53.6 (9.4) | .595 |
| t(9;11)/KMT2A-MLLT3 | 3 (5.4) | 100 | |
| t(11;19)/KMT2A-MLLT1 | 14 (25.0) | 57.1 (13.2) | |
| Other KMT2A-r | 11 (19.6) | 50.0 (17.7) | |
| Interfant-06 risk group† | |||
| Interfant-MR | 23 (41.1) | 72.9 (9.5) | .051 |
| Interfant-HR | 33 (58.9) | 45.4 (9.0) | |
| Day 8 prednisolone response | |||
| PGR | 31 (55.4) | 60.1 (8.9) | .615 |
| PPR | 25 (44.6) | 52.5 (10.4) | |
| BM status at TP2‡ | |||
| M1 | 47 (90.4) | 59.5 (7.2) | .205 |
| M2 | 4 (7.7) | 25.0 (21.7) | |
| M3 | 0 (0.0) | — | |
| Not evaluated | 1 (1.9) | — | |
| FCM-MRD at TP2‡ | |||
| <0.01% | 29 (56.9) | 65.5 (8.8) | .036 |
| ≥0.01% | 19 (37.3) | 36.8 (11.1) | |
| Not evaluated | 3 (5.9) | — | |
| FCM-MRD at TP3‡ | |||
| <0.01% | 33 (64.7) | 69.6 (8.0) | <.001 |
| ≥0.01% | 8 (15.9) | 0 | |
| Not evaluated | 10 (19.6) | — |
MR, medium risk; PGR, prednisolone good responder; TP2, time point 2 (at the end of induction); TP3, time point 3 (at the end of early consolidation).
CNS-3, WBC ≥ 5/μL in cerebrospinal fluid (CSF) with blasts; CNS-2, WBC < 5/μL in CSF with blasts; CNS-1, absence of blasts in CSF regardless of the number of WBCs.
Interfant-06 HR, KMT2A-r, and age <6 mo either with WBC ≥ 300 ×109/L or PPR; MR, other KMT2A-r.
Fifty-one patients were evaluated (4 patients withdrew from the study before CR evaluation and the MRD target was not set up for 1 patient).